"Genes, BRCA2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human chromosome 13 at locus 13q12.3. Mutations in this gene predispose humans to breast and ovarian cancer. It encodes a large, nuclear protein that is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev 2000;14(11):1400-6)
| Descriptor ID |
D024522
|
| MeSH Number(s) |
G05.360.340.024.340.375.249.105 G05.360.340.024.340.415.400.105
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Genes, BRCA2".
Below are MeSH descriptors whose meaning is more specific than "Genes, BRCA2".
This graph shows the total number of publications written about "Genes, BRCA2" by people in this website by year, and whether "Genes, BRCA2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 1 | 2 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Genes, BRCA2" by people in Profiles.
-
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study. Gynecol Oncol. 2021 05; 161(2):512-515.
-
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018 12 27; 379(26):2495-2505.
-
Kub5-Hera RPRD1B Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers. Clin Cancer Res. 2018 12 15; 24(24):6459-6470.
-
Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 04; 145(1):122-129.
-
Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol. 2014 Oct 10; 32(29):3275-83.
-
Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers. Gynecol Oncol. 2014 May; 133(2):283-6.
-
Breast cancer risk: evaluating the risk and role of genetic testing. J Okla State Med Assoc. 2002 Oct; 95(10):663-4; quiz 665-6.